Vomiting News and Research

RSS

Vomiting is the process the body uses to eject some or all of the contents of the stomach through the mouth.

Taiho Pharmaceutical receives approval to market ABRAXANE IV Infusion 100 mg in Japan

Abraxis BioScience, Inc., a fully integrated, global biotechnology company, today announced that Taiho Pharmaceutical Co., Ltd. has received approval from the Ministry of Health, Labor and Welfare to market ABRAXANE IV Infusion 100 mg, Paclitaxel Injection (Suspension with Albumin), for use in the treatment of breast cancer. The New Drug Application (J-NDA) for ABRAXANE was filed with the Ministry of Health, Labor and Welfare in 2008.

23 Jul 2010

Boehringer Ingelheim's VERxVE study of nevirapine meets primary endpoint

New data were presented today at the 18th International AIDS Conference from the VERxVE study that show an investigational, once-daily extended-release (400 mg QD) formulation of nevirapine was non-inferior to twice-daily immediate release Viramune® (nevirapine) tablets (200 mg BID), both in combination with Truvada® (tenofovir and emtricitabine) tablets in treatment-naive HIV-1 infected patients through 48 weeks.

23 Jul 2010

Three toxins in food identified as triggers to gluten intolerance: study

Coeliac disease cause by intolerance to gluten present in food and drinks like bread, pasta, cereals, biscuits and beer commonly affects many people all over the world. This affects 1 percent of all people in UK, especially women. Patients are advised to stay away from gluten to prevent damage to their intestines. In spite of this in five years most patients develop problems in their intestines. A gluten free diet is also difficult to maintain. Possible symptoms include diarrhoea, nausea and vomiting, recurrent stomach pain, tiredness, headaches, weight loss and mouth ulcers. These may be mild, moderate or severe in different individuals.

22 Jul 2010

Anthem Blue Cross and Blue Shield launches initiative to educate consumers on how to best access ER alternatives

At a time when health care costs continue to rise and hospitals are advertising emergency room availability, it is becoming more important to educate consumers on how to best access ER alternatives and receive the same care with less out-of-pocket cost. If a primary care physician isn't available, retail health clinics, walk-in doctor offices and urgent care centers can take less time and cost about the same as a regular doctor visit.

22 Jul 2010

NACI updates, strengthens statement related to the use of rotavirus vaccines in Canada

This week, the National Advisory Committee on Immunization updated and strengthened its statement related to the use of rotavirus vaccines in Canada. Rotavirus infection is the most common cause of severe gastroenteritis in children under the age of three. The NACI statement now includes Grade A recommendations (good evidence to recommend immunization) for healthy and preterm infants.

21 Jul 2010

Genentech disappointed with FDA ODAC's recommendation against Avastin

Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to one that use of Avastin® (bevacizumab) in combination with paclitaxel for previously untreated (first-line) advanced HER2-negative breast cancer be removed from Avastin's U.S. label.

21 Jul 2010

New & improved rotavirus vaccine to be trialed in Melbourne

Now a vaccine is being developed against rotavirus in Melbourne. At present Australian children were given rotavirus vaccine at the age of six to eight weeks since 2007. This new vaccine will be applicable to infants from birth.

20 Jul 2010

Phase 3 study: Tapentadol ER lowers incidence of gastrointestinal adverse events

A Phase 3 open-label study, recently published online by Pain Practice, has compared tapentadol extended release tablets, an investigational pain medication, to an existing prescription pain medication, oxycodone controlled release tablets.

20 Jul 2010

Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference

Abbott today presented 48-week findings comparing an HIV regimen of its protease inhibitor (PI), Kaletra® (lopinavir/ritonavir), and Merck's integrase inhibitor, Isentress® (raltegravir), to a traditional HIV regimen of Kaletra and the nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs) in Truvada® (tenofovir and emtricitabine) in antiretroviral-naive adult patients. Efficacy data were collected over the first 48 weeks of the 96-week PROGRESS (PROtease/InteGRasE Simplification Study) study.

20 Jul 2010

Phase 2 CUBICIN study for prosthetic joint infections meets primary endpoint

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced that its Phase 2 safety study of CUBICIN (daptomycin for injection) in the treatment of prosthetic joint infections caused by certain Gram positive pathogens met its study objectives. This study was a first-of-its-kind randomized controlled Phase 2 trial studying anti-infective therapy in the setting of 2-stage surgery for the replacement of infected prosthetic hip or knee joints.

19 Jul 2010

People needing non-emergent care can now turn to walk-in centers

For many, summer time means cook-outs, family hikes, and trips to the beach. However, while the good weather brings an increase in outdoor activities, for some it can also mean a trip to the local emergency room.

17 Jul 2010

Spanish scientists develop new parasite detection method to prevent Anisakidosis

A new method enables anisakids to be detected in any fish product, from a whole fish, fresh or frozen, to tinned fish and surimi. Developed by Spanish scientists, the system is based on molecular techniques and overcomes the limitations of traditional procedures.

16 Jul 2010

ACTOS offers safety profile regarding risk of CV events in people with type 2 diabetes: Takeda

The U.S. Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee held a joint meeting primarily focused on reviewing the cardiovascular safety of rosiglitazone, as presented by the FDA and GlaxoSmithKline. Following this two day discussion, Takeda Pharmaceuticals North America, Inc. ("Takeda") underscores its position that ACTOS (pioglitazone HCl) offers an established safety profile regarding the risk of CV events in people living with type 2 diabetes.

16 Jul 2010

NIH announces 5 more years of funding for Consortium of Food Allergy Research

Today, the National Institutes of Health announce that the Consortium of Food Allergy Research (CoFAR), established in 2005, will be funded for five more years. CoFAR will continue to foster new approaches to prevent and treat food allergies and also expand in scope to include research on the genetic causes underlying food allergy and studies of food allergy-associated eosinophilic gastrointestinal diseases (EGIDs).

15 Jul 2010

MAP Pharmaceuticals reports results from LEVADEX PK and safety clinical trial in smokers, non-smokers

MAP Pharmaceuticals, Inc. today announced results from a clinical trial comparing the pharmacokinetics (PK) and safety of LEVADEX™ orally inhaled migraine therapy with intravenous dihydroergotamine mesylate (DHE) in smokers and non-smokers. The trial was designed to measure whether systemic absorption and exposure in smokers is greater than in non-smokers. In the trial, the systemic absorption of LEVADEX was not higher and systemic exposure to DHE was not greater in smokers than in non-smokers.

13 Jul 2010

GE Healthcare Medical Diagnostics reintroduces Optison ultrasound contrast agent for echocardiograms

GE Healthcare Medical Diagnostics today announced the market reintroduction of Optison™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), a diagnostic ultrasound contrast agent for use in select echocardiograms. Optison is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricle and to improve the delineation of the left ventricular endocardial borders. The safety and efficacy of Optison with exercise stress or pharmacologic stress testing have not been established.

12 Jul 2010

Pfizer to present results of hemophilia studies at WFH 2010 Congress

Pfizer Inc, the world's leading biopharmaceutical company, today announced that the results of a number of hemophilia studies will be presented at the World Federation of Hemophilia 2010 Congress taking place July 10-14, 2010, in Buenos Aires, Argentina. Key research includes a pre-clinical evaluation of recombinant factor Xa as a potential new approach to restoring hemostasis, as well as a study assessing the potential for an engineered recombinant factor VIIa molecule to improve therapeutic outcomes in mouse models of hemophilia.

9 Jul 2010

UC San Diego professor to establish new Peru/Brazil ICEMR to help control malaria

Tropical disease specialist Joseph Vinetz, MD, of the University of California, San Diego School of Medicine will lead an ambitious multi-national effort to help control and eventually conquer malaria, establishing a new Peruvian/Brazilian International Center of Excellence in Malaria Research Center with a seven-year, $9.2 million grant from the National Institutes of Health.

9 Jul 2010

Department of Agriculture asks consumers to discard Milky Way Farm's hard cheddar cheese

The Department of Agriculture today advised consumers who purchased aged hard cheddar cheese made with raw milk from Milky Way Farm in Troy, Bradford County, to discard the product immediately because of potential bacterial contamination. The Bureau of Food Safety has identified 20 pounds of raw milk cheddar cheese that entered the consumer market.

9 Jul 2010

Accudial's weight-based rotating labels prevent underdosing and overdosing in children's OTC medications

There is plenty to worry about when it comes to the job of parenting. However, wondering if a child is receiving the correct amount of over-the-counter (OTC) medication can now be a concern of the past, thanks to Children's AccuDial(R), a patented new line of children's medication available across Canada, with a dosing system based on body weight, not age.

9 Jul 2010

Vomiting News and Research

Further Reading

Taiho Pharmaceutical receives approval to market ABRAXANE IV Infusion 100 mg in Japan

Boehringer Ingelheim's VERxVE study of nevirapine meets primary endpoint

Three toxins in food identified as triggers to gluten intolerance: study

Anthem Blue Cross and Blue Shield launches initiative to educate consumers on how to best access ER alternatives

NACI updates, strengthens statement related to the use of rotavirus vaccines in Canada

Genentech disappointed with FDA ODAC's recommendation against Avastin

New & improved rotavirus vaccine to be trialed in Melbourne

Phase 3 study: Tapentadol ER lowers incidence of gastrointestinal adverse events

Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference

Phase 2 CUBICIN study for prosthetic joint infections meets primary endpoint

People needing non-emergent care can now turn to walk-in centers

Spanish scientists develop new parasite detection method to prevent Anisakidosis

ACTOS offers safety profile regarding risk of CV events in people with type 2 diabetes: Takeda

NIH announces 5 more years of funding for Consortium of Food Allergy Research

MAP Pharmaceuticals reports results from LEVADEX PK and safety clinical trial in smokers, non-smokers

GE Healthcare Medical Diagnostics reintroduces Optison ultrasound contrast agent for echocardiograms

Pfizer to present results of hemophilia studies at WFH 2010 Congress

UC San Diego professor to establish new Peru/Brazil ICEMR to help control malaria

Department of Agriculture asks consumers to discard Milky Way Farm's hard cheddar cheese

Accudial's weight-based rotating labels prevent underdosing and overdosing in children's OTC medications

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News